Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesOpthea Ltd

Opthea Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None AUD 0.00(0%)
Last update at 2026-11-11T06:45:03.829877Z
Market Cap
17.78M

Momentum Score

…

Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.01
Low
0.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Opthea Ltd is an Australian clinical-stage biopharmaceutical company developing therapies for retinal vascular diseases; its lead candidate OPT-302 is a VEGF-C/D inhibitor intended to be used with existing anti-VEGF-A agents. Long-term growth drivers include unmet need for improved and longer-lasting treatments for wet age-related macular degeneration and diabetic eye disease, potential regulatory approvals, and commercial adoption if clinical trials confirm additive benefit.

Investors should monitor clinical and regulatory outcomes, competitive pressure from established and emerging anti-VEGF and longer-acting therapies, and financing and dilution risk given the company's pre-revenue clinical-stage status.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
-0.02M
Revenue Per Share
-
Gross Profit TTM
-0.02M
Debt / Equity
-1.87
ROE
-3383.08%
Net Debt
-30.82M
ROCE
-40.34%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax 330.24M -169.74M -229.65M -148.45M -99.12M
Net income 330.44M -162.79M -220.24M -142.52M -92.82M
Selling general administrative 8.04M 20.54M 15.49M 27.84M 17.83M
Gross profit - 0.03M 0.12M 0.11M 0.09M
Reconciled depreciation 0.00M 0.09M 0.10M 0.10M 0.08M
Ebit - -123.28M -199.39M -146.80M -93.72M
Ebitda - -123.19M -199.29M -146.70M -93.65M
Depreciation and amortization - 0.09M 0.10M 0.10M 0.08M
Operating income -11.95M -155.76M -191.84M -146.80M -93.72M
Other operating expenses - 155.79M 191.97M 150.13M 96.63M
Interest expense 11.06M 46.46M 30.26M 13.46M 0.24M
Tax provision -0.21M -6.95M -9.41M -5.93M -6.30M
Interest income 1.04M 5.53M 3.39M 1.58M 0.24M
Net interest income -10.02M -40.92M -26.87M -10.23M 0.24M
Income tax expense - -6.95M -9.41M -5.93M -6.30M
Total revenue 0.00M 0.03M 0.12M 0.11M 0.09M
Total operating expenses 11.95M 155.79M 191.97M 150.13M 96.63M
Cost of revenue - - - 0.17M 0.16M
Total other income expense net 352.20M -13.98M -37.81M 11.81M -5.39M
Net income from continuing ops 330.44M -162.79M -220.24M -142.52M -92.82M
Net income applicable to common shares - -162.79M -220.24M -142.52M -92.82M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 31.93M 56.80M 188.79M 98.64M 60.05M
Other current assets - - - - 8.72M
Total liab 2.32M 257.87M 264.60M 104.40M 12.07M
Total stockholder equity 29.61M -201.07M -75.81M -5.76M 47.98M
Other current liab - 246.99M 24.84M 0.75M 0.64M
Common stock - - 466.08M 320.88M 235.28M
Capital stock 732.47M 497.49M 466.08M 320.88M 235.28M
Retained earnings -759.61M -742.50M -579.70M -359.37M -216.94M
Other liab - - - 0.01M 0.03M
Other assets - - - 0.05M 0.11M
Cash 30.02M 48.44M 172.47M 89.19M 44.63M
Cash and equivalents - - - 77.12M 32.78M
Total current liabilities 2.32M 257.87M 64.06M 18.65M 12.04M
Current deferred revenue - - 1.06M - -
Net debt - - -30.82M -89.01M -44.63M
Short term debt - - 0.09M 0.10M 0.00M
Short long term debt total - - 141.65M 0.18M -
Other stockholder equity - - - 20.09M 29.64M
Property plant equipment - - - 0.20M 0.03M
Total current assets 31.93M 56.80M 188.19M 98.39M 59.91M
Net tangible assets - - - -5.85M 47.98M
Net receivables - - 11.82M 6.56M 6.56M
Long term debt - - 141.55M 85.66M -
Accounts payable 2.32M 9.74M 38.06M 17.80M 11.40M
Accumulated other comprehensive income - - 37.81M 32.73M 29.64M
Non currrent assets other - - 0.47M 0.05M 0.11M
Non current assets total 0.00M 0.00M 0.60M 0.26M 0.14M
Capital lease obligations - 0.00M 0.09M 0.18M 0.00M
Long term debt total - - - 85.74M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.01M -0.03M -0.02M -0.02M
Change to liabilities - - - 7.30M 8.51M
Total cashflows from investing activities - -0.01M -0.03M -0.02M -0.02M
Net borrowings 0.00M -0.09M -0.09M 84.43M -0.09M
Total cash from financing activities -30.89M 34.77M 243.73M 248.70M 0.24M
Change to operating activities - - - 6.28M 5.85M
Net income 330.44M -162.79M -220.24M -211.88M -127.99M
Change in cash -43.38M -124.03M 83.28M 69.08M -92.53M
Begin period cash flow 73.94M 172.47M 89.19M 64.90M 157.43M
End period cash flow 30.02M 48.44M 172.47M 133.99M 64.90M
Total cash from operating activities - -158.64M -161.02M -179.30M -98.37M
Issuance of capital stock 0.00M 34.81M 158.82M 81.82M 0.00M
Depreciation - - 0.10M 0.15M 0.11M
Other cashflows from investing activities - - - - 0.00M
Change to account receivables - - -0.79M 0.56M 0.42M
Sale purchase of stock - 34.86M 243.82M 167.36M 0.26M
Other cashflows from financing activities - 0.05M 85.00M -0.03M -0.03M
Change to netincome - - - 7.86M 6.74M
Capital expenditures 0.00M 0.01M 0.03M 0.03M 0.02M
Change in working capital - 5.92M 17.30M 20.75M 20.22M
Stock based compensation - - 5.08M 5.83M 5.25M
Other non cash items - -158.64M 46.15M 11.77M 10.34M
Free cash flow -12.50M -158.66M -161.05M -179.34M -98.39M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CSL
CSL Ltd		 0.95
0.47%		 201.68 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 0.22
1.59%		 14.02 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.24
0.99%		 23.96 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.05
2.40%		 2.03 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Opthea Ltd

Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.

Level 9, Melbourne, VIC, Australia, 3000

61 3 9826 0399

https://opthea.com

33

Name Title Year Born
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. MD, CEO & Exec. Director 1974
Ms. Judith J. Robertson B.A., M.B.A. Chief Commercial Officer 1960
Dr. Joel Naor M.D., MBA, MSc Chief Medical Officer NA
Ms. Karen Adams CPA VP of Fin. & Company Sec. 1971
Mr. Timothy E. Morris CPA, CPA Chief Financial Officer 1961
Ms. Annie Lee Fin. & Operations Mang. NA
Dr. Michael Gerometta Ph.D. Head of Chemistry, Manufacturing & Controls Devel. 1964
Mr. Bruno Gagnon BPHARM, M.Sc. Sr. VP of Global Clinical Operations NA
Dr. Ian Leitch Director of Clinical Research 1963
Dr. James Goding Independent Consultant NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DRUG
CAD 32.00
+23.08%
CHR
CAD 35.50
+7.80%
HG
CAD 4.77
+7.19%
QTWO
CAD 1.73
+7.14%
PET
CAD 23.03
+7.02%
MUX
CAD 18.80
-17.69%
URE
CAD 0.96
-15.04%
WELL
CAD 3.62
-14.82%
ITH
CAD 2.01
-10.67%
SGML
CAD 7.52
-9.94%

Equity Sectors*

  • Basic Materials

    -3.56%

  • Communication Services

    +0.11%

  • Consumer Cyclical

    -0.57%

  • Consumer Defensive

    -0.30%

  • Energy

    +0.19%

  • Financial Services

    -0.06%

  • Healthcare

    -0.37%

  • Industrials

    -0.81%

  • Real Estate

    -0.85%

  • Technology

    -0.12%

  • Utilities

    -0.11%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…